Patient demographics and baseline characteristics
| . | Plerixafor (n = 148) . | Placebo (n = 154) . | P . |
|---|---|---|---|
| Median (± SD) age, y | 58.2 ± 8.4 | 58.4 ± 8.6 | .83 |
| Male sex, n (%) | 100 (67.6) | 107 (69.5) | .72 |
| Ethnic origin, n (%) | .10 | ||
| White | 117 (79.1) | 128 (83.1) | |
| Black | 18 (12.2) | 14 (9.1) | |
| Asian | 1 (0.7) | 3 (1.9) | |
| Hispanic/Latino | 11 (7.4) | 4 (2.6) | |
| Other | 1 (0.7) | 5 (3.2) | |
| Time from initial diagnosis to randomization, mo* | 10.7 (16.5) | 11.5 (16.9) | .66 |
| Stage of disease at initial diagnosis, n (%) | .09 | ||
| I | 28 (18.9) | 19 (12.3) | |
| II | 29 (19.6) | 44 (28.6) | |
| III | 91 (61.5) | 90 (58.4) | |
| Missing | 0 (0.0) | 1 (0.6) | |
| Remission status at enrollment, n (%) | .40 | ||
| First complete remission | 11 (7.4) | 18 (11.7) | |
| First partial remission | 129 (87.2) | 126 (81.8) | |
| Second complete remission | 0 (0.0) | 0 (0.0) | |
| Second partial remission | 8 (5.4) | 10 (6.5) | |
| Prior chemotherapy, n (%) | N/A | ||
| Yes | 144 (97.3) | 148 (96.1) | |
| No | 0 (0.0) | 0 (0.0) | |
| Missing | 4 (2.7) | 6 (3.9) | |
| Prior cytotoxic chemotherapy,† n (%) | 51 (34.5) | 48 (31.2) | |
| Prior radiotherapy, n (%) | .53 | ||
| Yes | 40 (27.0) | 47 (30.5) | |
| No | 106 (71.6) | 106 (68.8) | |
| Missing | 2 (1.4) | 1 (0.6) |
| . | Plerixafor (n = 148) . | Placebo (n = 154) . | P . |
|---|---|---|---|
| Median (± SD) age, y | 58.2 ± 8.4 | 58.4 ± 8.6 | .83 |
| Male sex, n (%) | 100 (67.6) | 107 (69.5) | .72 |
| Ethnic origin, n (%) | .10 | ||
| White | 117 (79.1) | 128 (83.1) | |
| Black | 18 (12.2) | 14 (9.1) | |
| Asian | 1 (0.7) | 3 (1.9) | |
| Hispanic/Latino | 11 (7.4) | 4 (2.6) | |
| Other | 1 (0.7) | 5 (3.2) | |
| Time from initial diagnosis to randomization, mo* | 10.7 (16.5) | 11.5 (16.9) | .66 |
| Stage of disease at initial diagnosis, n (%) | .09 | ||
| I | 28 (18.9) | 19 (12.3) | |
| II | 29 (19.6) | 44 (28.6) | |
| III | 91 (61.5) | 90 (58.4) | |
| Missing | 0 (0.0) | 1 (0.6) | |
| Remission status at enrollment, n (%) | .40 | ||
| First complete remission | 11 (7.4) | 18 (11.7) | |
| First partial remission | 129 (87.2) | 126 (81.8) | |
| Second complete remission | 0 (0.0) | 0 (0.0) | |
| Second partial remission | 8 (5.4) | 10 (6.5) | |
| Prior chemotherapy, n (%) | N/A | ||
| Yes | 144 (97.3) | 148 (96.1) | |
| No | 0 (0.0) | 0 (0.0) | |
| Missing | 4 (2.7) | 6 (3.9) | |
| Prior cytotoxic chemotherapy,† n (%) | 51 (34.5) | 48 (31.2) | |
| Prior radiotherapy, n (%) | .53 | ||
| Yes | 40 (27.0) | 47 (30.5) | |
| No | 106 (71.6) | 106 (68.8) | |
| Missing | 2 (1.4) | 1 (0.6) |